VC banks on CAR T through acoustic wave separation firm investment

By Dan Stanton

- Last updated on GMT

GettyImages/BackyardProduction
GettyImages/BackyardProduction

Related tags Chemical engineering

Venture capital company Dynamk Capital has invested in FloDesign Sonics citing its acoustic wave separation technology’s application in the growing CAR T cell sector.

The New Jersey-based life sciences backer has added FloDesign Sonics (FDS) to its portfolio, describing the investment as an entry into commercial CAR T and immunotherapy production advancement.

“FloDesign Sonics is fundamentally changing cell selection, handling and separation through application of gentle acoustic processing,”​ said Daniella Kranjac, co-founder and managing director of Dynamk Capital.

“We are thrilled to see the commercialisation of this technology in bioprocessing, and now FDS is set to innovate cell and gene therapy delivery, reducing cost and improving access to life-saving therapies, by enabling closed, automated, and gentle cell processing.”

Enabling the fourth pillar of modern medicine’

The firm’s acoustic wave separation (AWS) system uses a three-dimensional standing wave to trap and gather cells in the flow channel through a process called acoustophoresis. This allows particle separations that are more typically performed with porous filters or centrifuges but offers low-power, no-pressure-drop, no-clog, and no-shear, according to the company.

The platform was licensed by Pall in 2015​ as an alternative to tangential-flow filtration (TFF) and alternating tangential flow (ATF) in perfusion technologies, and more recently the firm has been pushing the tech towards cell and gene therapy applications.

Last September, FDS founder and CEO Stanley Kowalski spoke with Biopharma-Reporter on the back of a co-development deal with an undisclosed large biopharmaceutical firm to commercialise the acoustic-based unit operations in both concentration-wash and acoustic affinity cell separation (AACS) for production of a CAR T candidate.

“We believe we are really going to enable the CAR T therapies to lower the cost,”​ he told us at Biotech Week Boston. “We like to say we are enabling the fourth pillar of modern medicine.”

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Related suppliers

Follow us

Products

View more

Webinars